Trial Profile

A Phase I Study With Single/Multiple Dose Administered to Explore the Safety/Tolerability and Pharmacokinetics of GFH018 in the Treatment of Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GFH 018 (Primary)
Indications Liver cancer; Solid tumours; Thymic epithelial tumour
Focus Adverse reactions; First in man
Sponsors GenFleet Therapeutics

Most Recent Events

06 Jun 2023 Final results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
02 Feb 2023 Planned End Date changed from 1 Jun 2023 to 21 Feb 2023.
13 Sep 2022 Results (As of Jan 25, 2022, n=39, the dose escalation part) assessing the safety, pharmacokinetics and preliminary efficacy of GFH018 monotherapy in pts with advanced solid tumors presented at the 47th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com